• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

Federated Hermes Impact Opportunities Equity Fund Class F2 GBP Acc

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund ProviderHermes Fund Managers Ireland Ltd
Fund SummaryThe investment objective of the Fund is to achieve long term capital appreciation by investing in companies which will benefit from meeting the worlds environmental and social challenges.
SEDOL codeBD3FNV4
ISINIE00BD3FNV41
Fund codeHEIOA
ManagersMartin Todd, Mark Sherlock
Manager Tenure1 year
Morningstar CategoryGlobal Flex-Cap Equity
IMA SectorGlobal
Fund Size£273 million
Fund TypeOEIC
Management StyleActive
Ongoing Charge Figure (OCF)0.95%
Cavendish ongoing charge0.05%
FundsNetwork Service Fee0.20%
Minimum Initial Investment£25
Minimum Top Up£25
Minimum Monthly Investment£25
Sell Price£1.4103
Buy Price£1.4103
Price Change+1.1911%
Price Date28th September 2020
YieldCurrently unavailable
Dividend FrequencySemi-Annually
ISA EligibleYes
SIPP EligibleYes
Inception Date3rd April 2018
Fund StatusOPEN

3-year Mean Monthly Return: Currently unavailable

Annual Returns20192018
Fund Performance+9.97%+15.50%
Benchmark Performance
(Global Flex-Cap Equity)
+0.30%+1.07%
Time PeriodCumulativeBenchmark Performance
(Global Flex-Cap Equity)
Fund Compared to Benchmark
1 day1.19%-0.04%+1.23%
1 week0.04%-0.61%+0.65%
1 month-0.01%+2.94%-2.96%
3 months6.94%+23.54%-16.60%
6 months29.50%+1.89%+27.62%
1 year16.25%+1.72%+14.52%
3 yearsCurrently unavailableCurrently unavailableCurrently unavailable
5 yearsCurrently unavailableCurrently unavailableCurrently unavailable
10 yearsCurrently unavailableCurrently unavailableCurrently unavailable
YTD12.01%-1.27%+13.28%
Since inception13.21%Currently unavailableCurrently unavailable

Top 10 shares for this fund

Share NameCountryValue
Qiagen NVUSA4.65%
DexCom IncUSA4.42%
Lonza Group LtdCHE4.36%
Agilent Technologies IncUSA4.31%
Orsted A/SDNK4.30%
Illumina IncUSA4.28%
Novo Nordisk A/S BDNK4.07%
CSL LtdAUS4.07%
Ansys IncUSA4.06%
Abcam PLCGBR3.99%

Currently unavailable